摘要
目的:探讨氟哌啶醇和齐拉西酮单药方案对首发未用药精神分裂症伴急性激越症状患者疗效及安全性.方法:选取笔者所在医院2016年1月-2018年6月收治首发未用药精神分裂症伴急性激越症状患者130例,随机分为A组和B组,每组65例,分别采用氟哌啶醇和齐拉西酮治疗.比较两组近期疗效、治疗前后PANSS-EC量表评分、治疗后TESS量表评分、不良反应发生率及治疗前后QTc间期.结果:两组总有效率比较,差异无统计学意义(P>0.05);两组治疗后PANSS-EC量表评分均显著低于治疗前(P<0.05);两组治疗后PANSS-EC量表评分比较,差异无统计学意义(P>0.05);两组治疗后TESS量表评分比较,差异无统计学意义(P>0.05);B组震颤、静坐不能、心动过速及逆转性痉挛发生率均显著低于A组(P<0.05);两组嗜睡、肌强直、恶心呕吐及头晕发生率比较,差异无统计学意义(P>0.05);两组治疗前后QTc间期比较,差异无统计学意义(P>0.05).结论:采用氟哌啶醇和齐拉西酮单药治疗首发未用药精神分裂症伴急性激越症状患者,病情控制效果相似,但齐拉西酮更有助于降低不良反应发生风险.
Objective:To investigate the clinical efficacy and safety of Haloperidol and Ziprasidone monotherapy on first episode and untreated patients with acute agitation in schizophrenia.Method:A total of 130 first episode and untreated patients with acute agitation in schizophrenia were chosen from January 2016 to June 2018 in our hospital and randomly divided into the group A and the group B,65 cases in each group,treated with Haloperidol and Ziprasidone respectively.And the clinical efficacy for short-term and the PANSS-EC scale scores before and after treatment,the TESS scale scores after treatment,the incidences of adverse reactions and QTc interval before and after treatment of two groups were compared.Result:The total efficiency rate was compared between the two groups,and the difference was not statistically significant(P>0.05).The PANSS-EC scale scores after treatment of two groups were significantly lower than those before treatment(P<0.05).The PANSS-EC scale scores after treatment were compared between the two groups,and the differences were not statistically significant(P>0.05).The TESS scale scores after treatment were compared between the two groups,and the differences were not statistically significant(P>0.05).The incidences of tremor,cathisophobia,tachycardia and retrograde spasm in the group B were significantly lower than those of the group A(P<0.05).The incidences of somnolence,myotonia,nausea and vomiting and dizziness were compared between the two groups,and the differences were not statistically significant(P>0.05).The QTc interval before and after treatment of two groups were compared,and the differences were not statistically significant(P>0.05).Conclusion:Haloperidol and Ziprasidone monotherapy in the treatment of first episode and untreated patients with acute agitation in schizophrenia,the disease control effect is similar,but Ziprasidone is more helpful to reduce the risk of adverse reactions.
作者
王勇
陈祖金
骆书霞
刘珏蓬
陈丽
WANG Yong;CHEN Zujin;LUO Shuxia;LIU Juepeng;CHEN Li(Minkang Hospital of Suining City,Suining 629000,China)
出处
《中外医学研究》
2020年第9期29-32,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
